Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease–mineral and bone disorder

Pediatric Nephrology

Volumn 29, Issue 12, 2014, Pages 2289-2298

  Brandenburg, Vincent M ^a   Sinha, Smeeta ^b   Specht, Paula ^a   Ketteler, Markus ^c  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c KLINIKUM COBURG   (Germany)

Author keywords

Calcific uraemic arteriolopathy; Calcification; Calciphylaxis; Chronic kidney disease; Vascular disease

Indexed keywords

EID: 84892865007     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2746-7     Document Type: Article

References (51)

1. Angelis M, Wong LL, Myers SA, Wong LM (1997) Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 122:1083–1089
2. Selye H (1965) Calciphylaxis. Med Welt 24:1343
3. Selye J (1965) Calciphylaxis and calcergy. Orv Hetil 106:817–821
4. Selye H, Berczi I (1970) The present status of calciphylaxis and calcergy. Clin Orthop Relat Res 69:28–54
5. Gipstein RM, Coburn JW, Adams DA, Lee DB, Parsa KP, Sellers A, Suki WN, Massry SG (1976) Calciphylaxis in man. A syndrome of tissue necrosis and vascular calcification in 11 patients with chronic renal failure. Arch Intern Med 136:1273–1280
6. Brandenburg V, Al Fakhri N, Nemeth K, Goettsch C, Schurgers LJ, Vermeer C, Hofbauer LC, Schoppet M (2012) Calcification inhibitors in vascular calciphylaxis associated with normal renal function. Thromb Haemost 108:1241–1243
7. Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR (2007) Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 56:569–579
8. Brandenburg VM, Cozzolino M, Ketteler M (2011) Calciphylaxis: a still unmet challenge. J Nephrol 24:142–148
9. Zitt E, Konig M, Vychytil A, Auinger M, Wallner M, Lingenhel G, Schilcher G, Rudnicki M, Salmhofer H, Lhotta K (2013) Use of sodium thiosulphate in a multi-interventional setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant 28:1232–1240
10. Mochel MC, Arakaki RY, Wang G, Kroshinsky D, Hoang MP (2013) Cutaneous calciphylaxis: A retrospective histopathologic evaluation. Am J Dermatopathol 35:582–586
11. Kramann R, Brandenburg VM, Schurgers LJ, Ketteler M, Westphal S, Leisten I, Bovi M, Jahnen-Dechent W, Knuchel R, Floege J, Schneider RK (2012) Novel insights into osteogenesis and matrix remodelling associated with calcific uraemic arteriolopathy. Nephrol Dial Transplant 28:856–868
12. Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R (2013) Statin use and calcific uremic arteriolopathy: a matched case–control study. Am J Nephrol 37:325–332
13. Latus J, Kimmel M, Ott G, Ting E, Alscher MD, Braun N (2011) Early stages of calciphylaxis: are skin biopsies the answer? Case Rep Dermatol 3:201–205
14. Shroff R, Long DA, Shanahan C (2013) Mechanistic insights into vascular calcification in CKD. J Am Soc Nephrol 24:179–189
15. Rogers NM, Coates PT (2008) Calcific uraemic arteriolopathy: an update. Curr Opin Nephrol Hypertens 17:629–634
16. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W (2003) The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366
17. Hayashi M, Takamatsu I, Kanno Y, Yoshida T, Abe T, Sato Y (2011) A case–control study of calciphylaxis in Japanese end-stage renal disease patients. Nephrol Dial Transplant 27:1580–1584
18. Fine A, Zacharias J (2002) Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 61:2210–2217
19. Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, Stehman-Breen CO (2001) Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 60:324–332
20. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482–2494
21. Brandenburg VM, Kramann R, Specht P, Ketteler M (2012) Calciphylaxis in CKD and beyond. Nephrol Dial Transplant 27:1314–1318
22. Mawad HW, Sawaya BP, Sarin R, Malluche HH (1999) Calcific uremic arteriolopathy in association with low turnover uremic bone disease. Clin Nephrol 52:160–166
23. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G (1997) Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78–81
24. Krueger T, Westenfeld R, Schurgers L, Brandenburg V (2009) Coagulation meets calcification: the vitamin K system. Int J Artif Organs 32:67–74
25. Cozzolino M, Brandenburg V (2010) Warfarin: to use or not to use in chronic kidney disease patients? J Nephrol 23:648–652
26. Kruger T, Brandenburg V, Schlieper G, Marx N, Floege J (2013) Sailing between Scylla and Charybdis: oral long-term anticoagulation in dialysis patients. Nephrol Dial Transplant 28:534–541
27. Farah M, Crawford RI, Levin A, Chan YC (2011) Calciphylaxis in the current era: emerging ‘ironic’ features? Nephrol Dial Transplant 26:191–195
28. Goodkin DA, Larkina M, Robinson BM (2011) Iron and calciphylaxis. Nephrol Dial Transplant 26:3063–3064
29. Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, Rakugi H, Isaka Y (2010) Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol 21:1998–2007
30. Herrmann M, Kinkeldey A, Jahnen-Dechent W (2012) Fetuin-A function in systemic mineral metabolism. Trends Cardiovasc Med 22:197–201
31. Vedvyas C, Winterfield LS, Vleugels RA (2011) Calciphylaxis: A systematic review of existing and emerging therapies. J Am Acad Dermatol 67:253–260
32. Brandenburg VM, Schmitz S, Floege J, Amann K, Ketteler M (2011) Calciphylaxis. A call for interdisciplinary cooperation. Hautarzt 62:452–458
33. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr (2013) Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol 8:1162–1170
34. O’Neill WC (2013) Sodium thiosulfate: Mythical treatment for a mysterious disease? Clin J Am Soc Nephrol 8:1068–1069
35. Torregrosa JV, Duran CE, Barros X, Blasco M, Arias M, Cases A, Campistol JM (2012) Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 32:329–334
36. Girotto JA, Harmon JW, Ratner LE, Nicol TL, Wong L, Chen H (2001) Parathyroidectomy promotes wound healing and prolongs survival in patients with calciphylaxis from secondary hyperparathyroidism. Surgery 130:645–650
37. Bakkaloglu SA, Dursun I, Kaya A, Soylemezoglu O, Hasanoglu E, Buyan N (2007) Digital calciphylaxis progressing to amputation in a child on continuous ambulatory peritoneal dialysis. Ann Trop Paediatr 27:149–152
38. Feng J, Gohara M, Lazova R, Antaya RJ (2006) Fatal childhood calciphylaxis in a 10-year-old and literature review. Pediatr Dermatol 23:266–272
39. Toprak D, Bircan Z, Gokalp AS (2005) Calciphylaxis due to poor compliance in a child with end stage renal disease: a case report. Pediatr Int 47:95–98
40. Amin N, Gonzalez E, Lieber M, Salusky IB, Zaritsky JJ (2010) Successful treatment of calcific uremic arteriolopathy in a pediatric dialysis patient. Pediatr Nephrol 25:357–362
41. El Desoky SM, Bockenhauer D, Shroff R, Kari JA (2013) Subcutaneous nodules in a child on long-term dialysis: Questions. Pediatr Nephrol. doi: 10.1007/s00467-013-2571-z
42. Nigwekar SU, Wolf M, Sterns RH, Hix JK (2008) Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 3:1139–1143
43. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478–1483
44. Shroff R, Degi A, Kerti A, Kis E, Cseprekal O, Tory K, Szabo AJ, Reusz GS (2013) Cardiovascular risk assessment in children with chronic kidney disease. Pediatr Nephrol 28:875–884
45. Mitsnefes MM (2012) Cardiovascular disease in children with chronic kidney disease. J Am Soc Nephrol 23:578–585
46. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM (2008) Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 118:1748–1757
47. Araya CE, Fennell RS, Neiberger RE, Dharnidharka VR (2006) Sodium thiosulfate treatment for calcific uremic arteriolopathy in children and young adults. Clin J Am Soc Nephrol 1:1161–1166
48. Imam AA, Mattoo TK, Kapur G, Bloom DA, Valentini RP (2005) Calciphylaxis in pediatric end-stage renal disease. Pediatr Nephrol 20:1776–1780
49. Shroff RC, Shah V, Hiorns MP, Schoppet M, Hofbauer LC, Hawa G, Schurgers LJ, Singhal A, Merryweather I, Brogan P, Shanahan C, Deanfield J, Rees L (2008) The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol Dial Transplant 23:3263–3271
50. Pasch A, Schaffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S (2008) Sodium thiosulfate prevents vascular calcifications in uremic rats. Kidney Int 74:1444–1453
51. Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, Kitiyakara C, Klyprayong P, Disthabanchong S (2010) Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant 25:1923–1929